Janus kinase 2 inhibitors in myeloproliferative disorders

Eugenio Lucia, Anna Grazia Recchia, Massimo Gentile, Sabrina Bossio, Ernesto Vigna, Carla Mazzone, Antonio Madeo, Lucio Morabito, Vincenzo Gigliotti, Laura De Stefano, Nadia Caruso, Pasquale Servillo, Stefania Franzese, Maria Grazia Bisconte, Carlo Gentile, Fortunato Morabito

Research output: Contribution to journalArticle

Abstract

Importance of the field: JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2 V617F mutations. Areas covered in this review: We discuss the physiopathology of the JAK2 signaling pathway and review clinical trials of JAK2 inhibitors for the treatment of MPD using papers and meeting abstracts published up to September 2010. What the reader will gain: This review helps in understanding the potential role of JAK2 inhibitors in MPD clinical trials and provides a comprehensive review regarding their efficacy and safety in these disorders. Take home message: JAK2 inhibitors may prove to be useful only for suppressing disease manifestations. However, unlike drugs such as IFN which are capable of eliminating the malignant clone, JAK2 inhibitors are unable to eradicate the disease. In fact, results to date indicate that although these inhibitors reduce splenomegaly and alleviate constitutional symptoms irrespective of JAK2 mutational status, most have only a modest impact on the JAK2V617F allele burden. Considering the relevant risk of serious complications in patients undergoing splenectomy, these drugs could find a suitable indication in patients with myelofibrosis awaiting bone marrow transplantation.

Original languageEnglish
Pages (from-to)41-59
Number of pages19
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2011

Keywords

  • essential thrombocythemia
  • JAK2
  • JAK2 inhibitors
  • myelofibrosis
  • Philadelphia chromosome-negative myeloproliferative neoplasms
  • polycythemia vera
  • therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Janus kinase 2 inhibitors in myeloproliferative disorders'. Together they form a unique fingerprint.

  • Cite this

    Lucia, E., Recchia, A. G., Gentile, M., Bossio, S., Vigna, E., Mazzone, C., Madeo, A., Morabito, L., Gigliotti, V., Stefano, L. D., Caruso, N., Servillo, P., Franzese, S., Bisconte, M. G., Gentile, C., & Morabito, F. (2011). Janus kinase 2 inhibitors in myeloproliferative disorders. Expert Opinion on Investigational Drugs, 20(1), 41-59. https://doi.org/10.1517/13543784.2011.538382